Cargando…
Treatment Outcomes and Risk Factors of Multidrug-Resistant Tuberculosis Patients in Xi’an China, a Retrospective Cohort Study
BACKGROUND: Long-term regimens are widely used for multidrug-resistant tuberculosis (MDR-TB) in North-West China; however, risk factors associated with the treatment outcomes are not well known. METHODS: This was a retrospective cohort study of MDR-TB patients treated with longer regimen in Xi’an fr...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438796/ https://www.ncbi.nlm.nih.gov/pubmed/36060236 http://dx.doi.org/10.2147/IDR.S376177 |
_version_ | 1784781903883141120 |
---|---|
author | Ma, Jin-Bao Zeng, Ling-Cheng Ren, Fei Dang, Li-Yun Luo, Hui Wu, Yan-Qin Yang, Xin-Jun Li, Rong Yang, Han Xu, You |
author_facet | Ma, Jin-Bao Zeng, Ling-Cheng Ren, Fei Dang, Li-Yun Luo, Hui Wu, Yan-Qin Yang, Xin-Jun Li, Rong Yang, Han Xu, You |
author_sort | Ma, Jin-Bao |
collection | PubMed |
description | BACKGROUND: Long-term regimens are widely used for multidrug-resistant tuberculosis (MDR-TB) in North-West China; however, risk factors associated with the treatment outcomes are not well known. METHODS: This was a retrospective cohort study of MDR-TB patients treated with longer regimen in Xi’an from 2017 to 2019. Risk factors associated with the treatment outcome were analyzed using multiple logistic regression. RESULTS: Of the 446 patients with MDR-TB included, 215 were cured, 84 completed treatment, 23 failed treatment, 108 were lost to follow-up, and 16 died. Unfavorable outcome risk factors were age >40 years (OR = 3.25, 95% CI = 2.12–4.98), male sex (OR = 2.53, 95% CI = 1.52–4.22), and re-treated tuberculosis (OR = 1.70, 95% CI = 1.11–2.61), whereas poor treatment outcome risk factors were age >40 years (OR = 5.51, 95% CI = 2.52–12.07), fluoroquinolones not used in the regimen (OR = 3.31, 95% CI = 1.45–7.51), and smear-positive (OR = 4.0, 95% CI = 1.47–10.8). CONCLUSION: In Xi’an, MDR-TB treatments with long-term regimens had low success rates, and age, sex, and tuberculosis treatment history were risk factors of MDR-TB treatment outcomes. |
format | Online Article Text |
id | pubmed-9438796 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-94387962022-09-03 Treatment Outcomes and Risk Factors of Multidrug-Resistant Tuberculosis Patients in Xi’an China, a Retrospective Cohort Study Ma, Jin-Bao Zeng, Ling-Cheng Ren, Fei Dang, Li-Yun Luo, Hui Wu, Yan-Qin Yang, Xin-Jun Li, Rong Yang, Han Xu, You Infect Drug Resist Original Research BACKGROUND: Long-term regimens are widely used for multidrug-resistant tuberculosis (MDR-TB) in North-West China; however, risk factors associated with the treatment outcomes are not well known. METHODS: This was a retrospective cohort study of MDR-TB patients treated with longer regimen in Xi’an from 2017 to 2019. Risk factors associated with the treatment outcome were analyzed using multiple logistic regression. RESULTS: Of the 446 patients with MDR-TB included, 215 were cured, 84 completed treatment, 23 failed treatment, 108 were lost to follow-up, and 16 died. Unfavorable outcome risk factors were age >40 years (OR = 3.25, 95% CI = 2.12–4.98), male sex (OR = 2.53, 95% CI = 1.52–4.22), and re-treated tuberculosis (OR = 1.70, 95% CI = 1.11–2.61), whereas poor treatment outcome risk factors were age >40 years (OR = 5.51, 95% CI = 2.52–12.07), fluoroquinolones not used in the regimen (OR = 3.31, 95% CI = 1.45–7.51), and smear-positive (OR = 4.0, 95% CI = 1.47–10.8). CONCLUSION: In Xi’an, MDR-TB treatments with long-term regimens had low success rates, and age, sex, and tuberculosis treatment history were risk factors of MDR-TB treatment outcomes. Dove 2022-08-29 /pmc/articles/PMC9438796/ /pubmed/36060236 http://dx.doi.org/10.2147/IDR.S376177 Text en © 2022 Ma et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Ma, Jin-Bao Zeng, Ling-Cheng Ren, Fei Dang, Li-Yun Luo, Hui Wu, Yan-Qin Yang, Xin-Jun Li, Rong Yang, Han Xu, You Treatment Outcomes and Risk Factors of Multidrug-Resistant Tuberculosis Patients in Xi’an China, a Retrospective Cohort Study |
title | Treatment Outcomes and Risk Factors of Multidrug-Resistant Tuberculosis Patients in Xi’an China, a Retrospective Cohort Study |
title_full | Treatment Outcomes and Risk Factors of Multidrug-Resistant Tuberculosis Patients in Xi’an China, a Retrospective Cohort Study |
title_fullStr | Treatment Outcomes and Risk Factors of Multidrug-Resistant Tuberculosis Patients in Xi’an China, a Retrospective Cohort Study |
title_full_unstemmed | Treatment Outcomes and Risk Factors of Multidrug-Resistant Tuberculosis Patients in Xi’an China, a Retrospective Cohort Study |
title_short | Treatment Outcomes and Risk Factors of Multidrug-Resistant Tuberculosis Patients in Xi’an China, a Retrospective Cohort Study |
title_sort | treatment outcomes and risk factors of multidrug-resistant tuberculosis patients in xi’an china, a retrospective cohort study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9438796/ https://www.ncbi.nlm.nih.gov/pubmed/36060236 http://dx.doi.org/10.2147/IDR.S376177 |
work_keys_str_mv | AT majinbao treatmentoutcomesandriskfactorsofmultidrugresistanttuberculosispatientsinxianchinaaretrospectivecohortstudy AT zenglingcheng treatmentoutcomesandriskfactorsofmultidrugresistanttuberculosispatientsinxianchinaaretrospectivecohortstudy AT renfei treatmentoutcomesandriskfactorsofmultidrugresistanttuberculosispatientsinxianchinaaretrospectivecohortstudy AT dangliyun treatmentoutcomesandriskfactorsofmultidrugresistanttuberculosispatientsinxianchinaaretrospectivecohortstudy AT luohui treatmentoutcomesandriskfactorsofmultidrugresistanttuberculosispatientsinxianchinaaretrospectivecohortstudy AT wuyanqin treatmentoutcomesandriskfactorsofmultidrugresistanttuberculosispatientsinxianchinaaretrospectivecohortstudy AT yangxinjun treatmentoutcomesandriskfactorsofmultidrugresistanttuberculosispatientsinxianchinaaretrospectivecohortstudy AT lirong treatmentoutcomesandriskfactorsofmultidrugresistanttuberculosispatientsinxianchinaaretrospectivecohortstudy AT yanghan treatmentoutcomesandriskfactorsofmultidrugresistanttuberculosispatientsinxianchinaaretrospectivecohortstudy AT xuyou treatmentoutcomesandriskfactorsofmultidrugresistanttuberculosispatientsinxianchinaaretrospectivecohortstudy |